Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platform TrialEvinova’s Digital Solution Will be Used by Study Sites to Monitor Patients Enrolled in Quantum Leap’s I-SPY 2.2 at Risk of Developing Interstitial Lung Disease
Quantum Leap Healthcare Collaborative Announces Completion of Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast CancerSan Francisco, CA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor and operator of the I-SPY 2 Trial, announces the completion of enrollment for two arms of the I-SPY 2 Trial. The goal was to evaluate the safety and efficacy of datopotamab deruxtecan as single agent therapy or in combination durvalumab.
Second generation of I-SPY 2 TRIAL design is driving the “precise” in precision medicineGroundbreaking I-SPY 2.2 TRIAL, an innovative trial model Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerSeattle, WA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SEATTLE, August 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient has been dosed in their clinical trial evaluating Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.
